Stay updated with breaking news from Relocation Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 2, 2024, at 11:30 AM CDT CatalYm today announced that positive new follow-up results from its ongoing "GDFATHER"
Oral presentation in "Developmental Therapeutics-Immunotherapy" session on Sunday, June 4 at 9:45 AM CDT CatalYm today announced that the first results from its ongoing Phase 2a trial "GDFATHER-2"
FinancialContent fully hosted finance channel
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for
CatalYmtoday announced the close of a EUR 50 million (USD 49 million) Series C financing round. The oversubscribed round was co-led by new investors, Brandon Capital and Jeito Capital with participation